Abstract: AZGP1 is a negative regulator of angiogenesis, such that loss of AZGP1 promotes angiogenesis in prostate cancer. AZGP1 likely exerts heterotypical effects on cells in the tumor microenvironment, such as stromal and endothelial cells. This study sheds light on the anti-angiogenic characteristics of AZGP1 in the prostate and provides a rationale to target AZGP1 to inhibit prostate cancer progression.
Introduction
Zinc-alpha-2-glycoprotein (AZGP1) is a well-established prognostic biomarker in prostate cancer (PCa). Clinical observations consistently link the loss of AZGP1 expression to aggressive disease, metastasis, and poor patient outcomes. Despite its clinical relevance, the biological function of AZGP1 has been a subject of debate due to inconsistent results in laboratory settings. This study addresses the "AZGP1 paradox" by investigating whether its primary role lies not in direct tumor cell growth, but in the regulation of the tumor microenvironment.
Methods
The research team employed a multi-faceted experimental design:
- Genetic Modulation: Lentiviral systems were used to knock out or overexpress AZGP1 in human PCa cell lines (PC3, DU145, LNCaP, 22Rv1) and patient-derived xenograft (PDX) models.
- In Vitro Assays: Standard proliferation, migration, and invasion assays were conducted to evaluate cell-autonomous effects.
- Animal Models: The study utilized AZGP1 knockout mice to observe prostatic changes over time and immune-deficient (NSG) mice for human cancer cell xenografts.
- Proteomics and Clinical Validation: Mass spectrometry was used for protein profiling, and results were validated using a human Tissue Microarray (TMA) of 215 radical prostatectomy samples.
Results
The In Vitro Paradox
A central finding of the study was that AZGP1 levels had no measurable impact on cancer cells grown in isolation. In assays for proliferation and invasion, modified cell lines behaved identically to controls. For example, in the LuCaP147 PDX model, overexpressing AZGP1 (AZGP1-OV) did not significantly alter luminescence (a proxy for cell viability) compared to control groups, despite successful protein expression confirmed via Western blot.
Regulation of Angiogenesis
The true function of AZGP1 emerged in vivo. AZGP1-deficient mice showed a significant increase in microvessel density by 6 months of age. In xenograft models, tumors overexpressing AZGP1 appeared pale and exhibited a quantitative reduction in CD31-positive microvessels. Proteomic analysis revealed that AZGP1 modulates key angiogenic pathways, suppressing MMP9—a protein that facilitates growth factor release—while increasing levels of inhibitory proteins like PDCD6 and EphA2.
Clinical Correlation
Analysis of the human TMA confirmed these findings in a clinical context. AZGP1 expression was negatively correlated with blood vessel density ($r = -0.19, p = 2 \times 10^{-7}$). Patients characterized by low AZGP1 expression and high vessel density experienced the worst disease-free survival outcomes, highlighting the clinical impact of this angiogenic switch.
Discussion
This study identifies AZGP1 as a secreted signaling molecule that acts as a "brake" on angiogenesis by inhibiting endothelial cell activity. The lack of effect in vitro explains previous contradictions in the literature, as the protein's function is inherently heterotypic, requiring interaction with the tumor stroma and vasculature.
While the study establishes AZGP1 as a potent anti-angiogenic factor, several questions remain. The specific cell-surface receptor on endothelial cells has yet to be identified. Furthermore, given AZGP1's structural similarity to MHC class I proteins, its potential role in immune modulation warrants further investigation. These findings provide a strong rationale for exploring AZGP1-based pathways as therapeutic targets to inhibit prostate cancer progression.
Summary updated